Zepbound (Tirzepatide) in Children Under 12: What Transition to Adult Care Looks Like

Why Zepbound Is Not Available for Children Under 12 Right Now

Tirzepatide (Zepbound) carries an FDA indication limited to adults with a body mass index (BMI) of 30 kg/m² or higher, or a BMI of 27 kg/m² or higher with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or obstructive sleep apnea. The approved label contains no pediatric dosing, no pediatric safety language, and no pediatric efficacy data. Prescribing Zepbound to a child younger than 12 is therefore off-label with essentially zero published pharmacokinetic or safety support in that age group.

The Regulatory Foundation

The FDA's approval of tirzepatide for chronic weight management (May 2022 for type 2 diabetes as Mounjaro, November 2023 for obesity as Zepbound) was based on the SURMOUNT trial program. SURMOUNT-1 (N=2,539) enrolled only adults aged 18 and older, reporting 20.9% mean body-weight reduction with tirzepatide 15 mg at 72 weeks versus 3.1% with placebo [1]. No participant in SURMOUNT-1 was younger than 18. FDA labeling explicitly states the drug has not been studied in pediatric patients [2].

The Ongoing Pediatric Research Gap

A dedicated pediatric tirzepatide trial (SURMOUNT-PEDS, NCT05558774) is actively enrolling adolescents aged 12 to 17 as of early 2025 [3]. The study's lower age boundary stops at 12. Children under 12 are excluded from that trial as well, meaning published controlled data for the youngest patients may remain unavailable for several more years. Extrapolating adult or adolescent pharmacokinetics to a 7-year-old or a 10-year-old is not clinically appropriate: hepatic enzyme activity, renal clearance rates, and gastrointestinal motility patterns differ substantially at those developmental stages.

What the Evidence Does Say About Obesity Treatment Before Age 12

The American Academy of Pediatrics (AAP) released its first comprehensive Clinical Practice Guideline on pediatric obesity in January 2023, published in Pediatrics. The guideline explicitly endorses early, aggressive treatment rather than watchful waiting. "Physicians should offer or refer children aged 2 years and older with obesity to intensive health behavior and lifestyle treatment," the guideline states [4].

Behavioral Intervention as the Required Starting Point

Intensive Health Behavior and Lifestyle Treatment (IHBLT) is the current cornerstone for children under 12. The AAP defines intensive as 26 or more contact hours per year with a multidisciplinary team. Data from a 2017 Cochrane review (across 70 randomized controlled trials, N>8,000 children) found that combined dietary, physical activity, and behavioral interventions produced a mean BMI z-score reduction of 0.06 to 0.15 standard deviations compared to control at 6-12 months [5]. That effect is modest by adult GLP-1 standards, which is precisely why families eventually seek pharmacological support.

Approved Pharmacotherapy for the Under-12 Age Band

Only one medication holds FDA approval specifically for obesity treatment in children under 12: orlistat (Xenical) was approved down to age 12, not younger. For children between 6 and 11 years, no FDA-approved anti-obesity medication for weight management exists as a labeled indication. Metformin is approved for type 2 diabetes in children aged 10 and older, and is sometimes used off-label to attenuate weight gain from certain medications, but it is not an obesity drug [6].

The gap below age 12 is real, recognized by the AAP, and is a key driver of why families ask about newer agents such as tirzepatide even for very young children with severe obesity.

Semaglutide as the Nearest Comparator in Adolescents

Semaglutide 2.4 mg weekly (Wegovy) received FDA approval for adolescents aged 12 and older in December 2022, based on the STEP TEENS trial. In STEP TEENS (N=201, ages 12-17), semaglutide 2.4 mg produced a mean 16.1% reduction in BMI at 68 weeks versus a 0.6% increase in the placebo group [7]. That is the closest pharmacological comparator to tirzepatide for an adjacent age group, but the 12-year age floor still leaves children younger than that without an approved GLP-1 or GIP/GLP-1 option.

Planning the Transition to Adult Care: A Clinical Framework

Transition planning in pediatric chronic disease management is not a single appointment. It is a multi-year process that ideally begins at age 14-16 for conditions requiring complex medication management. For a child under 12 who is currently being treated for severe obesity and is on the trajectory toward eventual GLP-1 or dual agonist therapy, the transition framework below reflects current best practices from both pediatric endocrinology and adult obesity medicine.

Phase 1: Foundation Building (Ages 6 to 11)

During this phase, the child is not a candidate for tirzepatide. The clinical goals are:

• Establishing a diagnosis of obesity using age- and sex-specific BMI percentiles (obesity defined as BMI at or above the 95th percentile for age and sex per CDC growth charts [8])
• Enrolling in an IHBLT program meeting the AAP's 26-contact-hour minimum
• Screening for and treating comorbidities: insulin resistance, dyslipidemia, elevated liver enzymes suggesting metabolic dysfunction-associated steatotic liver disease (MASLD), and obstructive sleep apnea
• Documenting the child's weight trajectory with a consistent electronic health record so the eventual adult provider has a longitudinal record

No tirzepatide. No semaglutide. Behavioral work is the medicine at this stage.

Phase 2: Adolescent Pharmacotherapy Window (Ages 12 to 17)

Once a patient crosses age 12, the pharmacological options expand. Semaglutide 2.4 mg (Wegovy) is now the guideline-consistent first pharmacological agent for adolescents with a BMI at or above the 95th percentile and at least one comorbidity, or a BMI at or above the 120% of the 95th percentile [4]. At this stage, a pediatric obesity specialist or pediatric endocrinologist should lead prescribing.

If the patient is age 12 or older and approaches the 18-year mark, their treating team should already be introducing the concept of adult care, explaining that:

1. Tirzepatide (Zepbound) becomes an option at age 18 with appropriate BMI criteria
2. Adult obesity medicine specialists manage GLP-1 and GIP/GLP-1 agents under different billing, monitoring, and prescribing frameworks than pediatric practices
3. A warm hand-off, meaning direct communication between the outgoing pediatric provider and the incoming adult provider, substantially reduces the risk of a treatment gap

Phase 3: The Transfer Appointment (Age 17 to 18)

The actual transfer to adult care should not happen the day a patient turns 18. The Society for Adolescent Health and Medicine (SAHM) recommends beginning the formal transition process no later than age 14, with a structured readiness assessment, a written transition plan, and at least one overlap visit where both the pediatric and adult provider can communicate directly [9]. In obesity medicine, the specific clinical stakes of that hand-off include:

• Ensuring the adult provider has the full medication history, including any prior trials of orlistat or semaglutide
• Confirming insurance coverage will continue uninterrupted, since many pediatric insurance plans differ substantially from adult plans
• Reviewing whether tirzepatide (Zepbound) is clinically appropriate as a next step, or whether continuing or optimizing the current adolescent regimen is preferred
• Addressing the patient's own health literacy and self-management readiness, which varies widely at age 18

A 2022 systematic review in Journal of Adolescent Health found that structured transition programs, compared to informal hand-offs, reduced the rate of treatment discontinuation in chronic disease management by approximately 28% across a range of conditions [10].

Phase 4: Adult Care Initiation and Tirzepatide Eligibility

Once the patient is 18 and meets BMI criteria, tirzepatide becomes a labeled option. Adult dosing starts at 2.5 mg subcutaneously once weekly and is titrated by 2.5 mg every four weeks as tolerated, targeting a maintenance dose of 5 mg, 10 mg, or 15 mg weekly [2]. Patients transitioning from semaglutide in adolescence do not require a washout period before starting tirzepatide, but clinicians should monitor for additive nausea during the switch.

In SURMOUNT-1, the 15 mg dose group achieved 22.5% mean weight loss at 72 weeks in the full analysis population [1]. Patients who have already established behavioral foundations in a structured pediatric program may respond at least as well, given that behavioral and lifestyle modification synergizes with GLP-1-based pharmacotherapy in adult trials.

Monitoring Parameters Specific to the Pediatric-to-Adult Transition

Transitioning patients carry risk profiles that differ from de-novo adult patients starting tirzepatide at age 35. The following monitoring table reflects both the SURMOUNT safety data and the pediatric obesity guideline recommendations that carry over into early adulthood.

| Parameter | Frequency | Notes | |---|---|---| | Body weight and BMI | Every 4 weeks during titration, then every 3 months | Use adult BMI thresholds after age 18 | | Fasting glucose and HbA1c | Baseline, 3 months, then every 6 months | Obesity in adolescents increases type 2 diabetes incidence 4-fold [11] | | Liver enzymes (ALT/AST) | Baseline, 6 months, annually | MASLD prevalence in adolescent obesity cohorts reaches 34-38% [12] | | Lipid panel | Baseline, annually | Dyslipidemia is common in transitioned patients | | Thyroid (TSH) | Baseline; repeat if symptomatic | Tirzepatide labeling includes a boxed warning for thyroid C-cell tumors based on rodent data [2] | | Gallbladder ultrasound | If symptomatic | Cholelithiasis risk is elevated with rapid weight loss at any age | | Bone density (DXA) | If history of eating disorder or low-calorie intake | Rapid weight loss in adolescence may affect peak bone mass |

Pancreatic enzyme elevation (lipase, amylase) should be checked if the patient reports persistent severe abdominal pain. SURMOUNT-1 reported acute pancreatitis in <0.1% of tirzepatide-treated adults, but the event warrants prompt evaluation regardless of age [1].

Practical Guidance for Families Navigating This Gap

Parents of children under 12 with severe obesity frequently arrive at telehealth consultations having read about tirzepatide's efficacy in adults and asking whether it can be used off-label in their child. The honest clinical answer: it should not be used in children under 12 with current evidence.

What to Ask the Pediatrician Right Now

• Is my child enrolled in or referred to an IHBLT program with at least 26 contact hours per year?
• Has a formal comorbidity screen been done in the last 12 months?
• Is my child's growth and weight being tracked on CDC growth charts each visit?
• Does our practice have a written transition plan for when my child approaches adolescence and eventually adulthood?

When to Seek a Subspecialist

Primary care is appropriate for the initial obesity diagnosis and for mild to moderate cases. A pediatric endocrinologist or a pediatric obesity medicine specialist should be involved when:

• BMI is at or above 140% of the 95th percentile
• Comorbidities including type 2 diabetes, severe sleep apnea, or pseudotumor cerebri are present
• The family is considering bariatric surgery evaluation (appropriate in select adolescents, not under-12 children without exceptional circumstances)
• Prior IHBLT has failed after a genuine 6-12 month trial

The Endocrine Society's 2023 Clinical Practice Guideline on obesity pharmacotherapy specifies that "pharmacological treatment should be considered as adjunct to lifestyle therapy in patients with obesity who have not achieved clinically meaningful weight loss with lifestyle intervention alone" [13]. For children under 12, that adjunct pharmacotherapy door is currently nearly closed.

The Regulatory Outlook: When Might Under-12 Data Arrive?

SURMOUNT-PEDS (NCT05558774) is expected to produce top-line results for the 12-17 age band in late 2025 or 2026 [3]. Whether Eli Lilly will subsequently pursue a pediatric investigation plan for children under 12 depends substantially on those results and on regulatory discussions with the FDA's Office of Pediatric Therapeutics. Under the Pediatric Research Equity Act (PREA), the FDA may require pediatric studies for a drug approved for a condition that occurs in pediatric patients, which obesity clearly does [14]. A formal Written Request or Required Pediatric Study from the FDA could compel Eli Lilly to study tirzepatide in younger children, but no such public requirement had been issued as of the date of this article.

Families should expect a realistic timeline of 2027-2029 before any label change affecting children under 12 could realistically emerge, assuming trial initiation in 2025-2026 and an 18-24 month trial duration followed by an FDA review period.

A Note on Compounded Tirzepatide and Children

Compounded tirzepatide has circulated through telehealth channels during periods of drug shortage. Prescribing compounded tirzepatide to a child under 12 carries additional risk beyond the standard off-label concerns: compounded preparations lack the bioequivalence testing, sterility assurance, and excipient characterization of the FDA-approved product. The FDA issued multiple warnings in 2023 and 2024 about compounded semaglutide and tirzepatide quality concerns [15]. Compounded tirzepatide should not be used in any pediatric patient regardless of age.